Novo Nordisk stock reports 7 percent Q2 sales growth

Published on 10/07/2026 at 13:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock posted 7 percent adjusted Q2 sales growth at constant exchange rates on August 4, 2026. The FDA extended denecimig review on October 2.

Bauhaus-Poster mit stilisierten Hormon-Molekülen in Blau, Weiß und Grau — Novo Nordisk A/S (DK0062498333): stilisierte Hormon-Moleküle als Bauhaus-Poster in Blau, Weiß und Grau auf Schwarz, Illustration mit AI erstellt.

Novo Nordisk stock is anchored by adjusted Q2 sales of DKK 78,488 million, which increased 7 percent at constant exchange rates on August 4, 2026. The company also reported adjusted operating profit of DKK 33,389 million, up 11 percent, giving investors a clearer measure of underlying performance after a difficult first half.

Q2 growth meets tougher outlook

According to Via Ritzau on August 4, 2026, adjusted sales grew 7 percent at constant exchange rates in Q2, while adjusted operating profit rose 11 percent. The figures exclude the non-recurring impact of US 340B provision reversals and a DKK 6,300 million non-cash impairment charge tied to pipeline assets.

The full-year 2026 adjusted sales and operating profit outlook now stands at 0 percent to minus 6 percent at constant exchange rates. That is an improvement from the previous range of minus 4 percent to minus 12 percent, although the revised range still points to a contraction rather than renewed full-year growth.

FDA delay shifts attention to 2027

According to Finanznachrichten, Novo said on October 2, 2026, that the US Food and Drug Administration had extended its denecimig review because of manufacturing-facility remediation. The regulator identified no deficiencies in the clinical efficacy or safety data, and Novo said the delay did not change its 2026 financial outlook.

Novo still aims to launch denecimig in the United States in the first half of 2027, pending a regulatory decision. That timing makes manufacturing execution a more immediate checkpoint than the drug's clinical profile, because the company linked the delay to facility work rather than trial results.

Consensus remains cautious

Gekko lists a Hold consensus from 7 firms, with an average 12-month price target of USD 46.14 and a target range of USD 40 to USD 47. Against the October 6, 2026 ADR value of USD 37.53, the average target lies 22.9 percent above the price.

The valuation debate therefore rests on a split picture: Q2 adjusted sales and operating profit improved at constant exchange rates, while the full-year guidance still allows a decline of up to 6 percent. Novo Nordisk's market capitalization was USD 166.7 billion as of October 6, 2026.

Next results arrive November 4

According to Novo Nordisk, the company will announce results for the first three quarters of 2026 on November 4, 2026, at 7:30 a.m. CEST. That report will test whether the Q2 growth rate can offset the pressure embedded in the full-year guidance.